New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Insmed, Inc. (INSM) vs Moderna, Inc. (MRNA)
- Insmed, Inc. INSM 141.33 −2.17%
- Moderna, Inc. MRNA 195.12 −2.11%
Insmed, Inc. and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $79.6B against $31.6B — 2.5× the size. Insmed, Inc. grew revenue faster over the last twelve months: 240.0% against 13.1%. Insmed, Inc. has the higher net margin (−39.9% vs −110.5%) and the lower return on invested capital (−247.6% vs −35.1%). Across the 18 metrics below, Insmed, Inc. leads on 11 and Moderna, Inc. on 7.
Valuation
Profitability
| Metric | INSM | MRNA | Biotechnology median |
|---|---|---|---|
| Gross margin | 84.40% | 28.00% | 70.18% |
| Operating margin | (37.11%) | (116.04%) | 0.00% |
| Net margin | (39.85%) | (110.46%) | 0.00% |
| Free cash flow margin | (41.30%) | (80.95%) | 0.00% |
| Return on equity | (72.45%) | (34.50%) | (51.58%) |
| Return on assets | (26.41%) | (21.79%) | (45.91%) |
| Return on invested capital | (247.55%) | (35.12%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack